TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod

Bulletin Express04-07 19:45

TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers.

The programme, cleared by the board on 7 April 2026, allows the Scheme Administrator to issue awards in the form of share options or share awards. Grants may be satisfied with treasury stock, newly issued H shares or existing H shares.

Implementation hinges on two conditions: 1. Shareholder approval via a special resolution at an upcoming extraordinary general meeting (EGM). 2. Listing Committee approval for the listing and dealing of any new H shares issued under the scheme.

Subject to EGM approval, the board also seeks authority for the Scheme Administrator to execute all documents and actions necessary to implement the plan.

A circular outlining full details and the EGM notice will be released in due course. Until formal approvals are obtained, shareholders and potential investors are advised to exercise caution when trading the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148728314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148728314","market":"hk","top_or_hot":-1,"title":"TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod","media":"Bulletin Express","content":"<p>TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers.</p>\n<p>The programme, cleared by the board on 7 April 2026, allows the Scheme Administrator to issue awards in the form of share options or share awards. Grants may be satisfied with treasury stock, newly issued H shares or existing H shares.</p>\n<p>Implementation hinges on two conditions:\n1. Shareholder approval via a special resolution at an upcoming extraordinary general meeting (EGM).\n2. Listing Committee approval for the listing and dealing of any new H shares issued under the scheme.</p>\n<p>Subject to EGM approval, the board also seeks authority for the Scheme Administrator to execute all documents and actions necessary to implement the plan.</p>\n<p>A circular outlining full details and the EGM notice will be released in due course. Until formal approvals are obtained, shareholders and potential investors are advised to exercise caution when trading the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-07 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers.</p>\n<p>The programme, cleared by the board on 7 April 2026, allows the Scheme Administrator to issue awards in the form of share options or share awards. Grants may be satisfied with treasury stock, newly issued H shares or existing H shares.</p>\n<p>Implementation hinges on two conditions:\n1. Shareholder approval via a special resolution at an upcoming extraordinary general meeting (EGM).\n2. Listing Committee approval for the listing and dealing of any new H shares issued under the scheme.</p>\n<p>Subject to EGM approval, the board also seeks authority for the Scheme Administrator to execute all documents and actions necessary to implement the plan.</p>\n<p>A circular outlining full details and the EGM notice will be released in due course. Until formal approvals are obtained, shareholders and potential investors are advised to exercise caution when trading the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1148728314","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148728314","pubTimestamp":1775562327,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"Tranthera-B董事会批准2026年H股奖励计划，寻求股东和港交所认可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers.\nThe programme, cleared by the board on 7 April 2026, allows the Scheme Administrator to issue awards in the form of share options or share awards. Grants may be satisfied with treasury stock, newly issued H shares or existing H shares.\nImplementation hinges on two conditions:\n1. Shareholder approval via a special resolution at an upcoming extraordinary general meeting (EGM).\n2. Listing Committee approval for the listing and dealing of any new H shares issued under the scheme.\nSubject to EGM approval, the board also seeks authority for the Scheme Administrator to execute all documents and actions necessary to implement the plan.\nA circular outlining full details and the EGM notice will be released in due course. Until formal approvals are obtained, shareholders and potential investors are advised to exercise caution when trading the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148728314","isCrawlerRequest":true}